Communiqués Verrica Pharmaceuticals Inc.

Actions

VRCA

US92511W2070

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
4,380 ^USD	-2,99%		+0,23%	-47,29%

30/09	Verrica Pharmaceuticals présentera une nouvelle analyse des données de YCANTH lors de deux prochains congrès de dermatologie	CI
10/09	Verrica Pharmaceuticals présente des données sur YCANTH et VP-315 lors de conférences de dermatologie	CI

Communiqués

30/09	Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences	AQ
10/09	Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences	AQ
08/09	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference	AQ
27/08	Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027	AQ
06/08	Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results	AQ
06/08	Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital	AQ
30/07	Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026	AQ
21/07	Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel	AQ
22/06	Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts	AQ
17/06	Torii Pharmaceutical - Announcement of First Dosing in Phase 3 Clinical Study of YCANTH/TO-208 for the Treatment of Common Warts	AQ
28/05	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference	AQ
13/05	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ	AQ
12/05	Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results	AQ
06/05	Verrica Pharmaceuticals : Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting	PU
05/05	Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting	AQ
05/05	Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026	AQ
09/04	Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting	AQ
06/04	Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference	AQ
11/03	Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results	AQ
05/03	Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026	AQ
23/02	Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference	AQ
12/02	Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer	AQ
09/02	Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical	AQ
07/01	Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts	AQ
24/11	Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway	AQ